In my latest article (http://seekingalpha.com/article/3943876-rapid-medical-testing-kits-huge-market) about Rapid medical Diagnostic Kits and investing in the industry, I point out the potential for EXAS and their Cologuard test. Here is a link to an article about colorectal cancer, the second most common malignancy among Israeli men and 4th among women. Its prevalence is rising among young adults 20-49 making EXAS a company to consider as a potentially good investment.

http://www.jpost.com/Business-and-Innovation/Health-and-Science/Prevalence-of-colorectal-cancer-remains-relatively-low-in-Israel-compared-to-other-OECD-nations-446660

Advertisements